Literature DB >> 20187822

Use of a constant rate infusion of insulin for the treatment of hyperglycemic, hypernatremic, hyperosmolar syndrome in an alpaca cria.

Teresa M Buchheit1, Carla S Sommardahl, Nicholas Frank, Jerry R Roberson.   

Abstract

CASE DESCRIPTION: A 3-day-old 9.5-kg (21-lb) female alpaca cria was examined because of lethargy and anorexia. CLINICAL
FINDINGS: Physical examination revealed hyperthermia, muscle fasciculations, and tremors of the head. Seizures were also observed, which indicated CNS dysfunction. Hyperosmolar syndrome (HOS) was diagnosed on the basis of hyperglycemia, hypernatremia, azotemia, high plasma osmolarity, and metabolic acidosis. TREATMENT AND OUTCOME: A constant rate infusion of regular insulin was administered with hypo-osmolar fluids to treat HOS, and blood glucose and sodium concentrations were successfully lowered. Neurologic deficits resolved with treatment, and the cria was discharged 11 days after admission. CLINICAL RELEVANCE: Administration of insulin as a bolus in addition to hypo-osmolar fluids has been advocated in the management of neonatal camelids with HOS. Administration of regular insulin via a constant rate IV infusion was used to successfully manage a neonatal camelid with HOS. This form of insulin administration may allow more control of glucose kinetics in these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20187822     DOI: 10.2460/javma.236.5.562

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  2 in total

1.  Failure of Passive Transfer in Camel Calves: 4 Cases (2010-2019).

Authors:  Amanda James; Joe Smith; Julie Sheldon; Ricardo Videla
Journal:  Case Rep Vet Med       Date:  2022-04-23

2.  Evaluation of glucose response to 3 types of insulin using a continuous glucose monitoring system in healthy alpacas.

Authors:  S R Byers; O M Beemer; A S Lear; R J Callan
Journal:  J Vet Intern Med       Date:  2014-06-25       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.